Related Experiment Video

Updated: Oct 10, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K

Biologics for pediatric psoriasis: A systematic review and meta-analysis

Helen Y Sun1,2, Kevin Phan1,2, Amy S Paller3

  • 1Faculty of Medicine and Health, University of New South Wales, Randwick, New South Wales, Australia.

Pediatric Dermatology
|December 10, 2021
PubMed

Insights

Biologic therapies are highly effective for treating moderate-to-severe pediatric psoriasis, showing significant improvements in skin condition with a good safety profile. This review summarizes key randomized controlled trials (RCTs) for children with psoriasis.

Area of Science:

  • Dermatology
  • Pediatrics
  • Pharmacology

Background:

  • Psoriasis is a chronic inflammatory skin condition affecting children.
  • Biologics offer a promising treatment avenue for pediatric psoriasis.
  • Existing research lacks a comprehensive review of biologic efficacy and safety in children.

Purpose of the Study:

  • To systematically review and meta-analyze randomized controlled trials (RCTs) on biologic treatments for pediatric psoriasis.
  • To assess the efficacy and safety of various biologics in managing moderate-to-severe psoriasis in children.

Main Methods:

  • Systematic review and meta-analysis of RCTs.
  • Searched multiple databases (Medline, Embase, PubMed, Cochrane) up to November 2020.
  • Employed random-effects models to pool effect sizes.

Main Results:

  • Five RCTs involving 768 pediatric patients were analyzed.
  • Biologics demonstrated a significantly high odds ratio (12.37) for achieving 75% Psoriasis Area and Severity Index improvement.
  • The odds ratio for adverse events was favorable (0.95) compared to placebo or non-biologic treatments.

Conclusions:

  • Biologic therapy is highly effective for pediatric moderate-to-severe psoriasis.
  • Biologics exhibit a favorable side effect profile in children.
  • Further research may address heterogeneity in study designs and agents.
Abstract

Keywords:
adolescentbiological therapychildpsoriasisquality of life

More Related Videos

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

532
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

793

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
27
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
18
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
256
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
20
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
19
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
9